Cocrystal Pharma, Inc. is a biotechnology company developing broad-spectrum antiviral therapeutics using structure-based drug discovery technologies, currently in preclinical and early clinical stages with no revenue yet.

# Company Overview Summary

## Company Name:
Cocrystal Pharma, Inc.

## Industry:
Biotechnology / Pharmaceutical Research and Development

## Core Focus:
- Developing novel antiviral therapeutics targeting serious and chronic viral diseases
- Employing structure-based drug discovery technologies combined with Nobel Prize-winning expertise
- Creating first-in-class and best-in-class antiviral drugs with broad-spectrum activity

## Technology and Approach:
- Utilizing computational chemistry, medicinal chemistry, X-ray crystallography, and proprietary high-resolution structural information
- Targeting essential viral replication enzymes, especially conserved regions, to develop inhibitors effective against multiple strains and mutants
- Designing small molecule therapeutics with mechanisms intended to prevent resistance development

## Target Viruses and Medical Needs:
- **Influenza Virus:** Developing oral and inhaled PB2 inhibitors (e.g., CC-42344), including candidates effective against resistant strains; plans for broader formulations
- **Coronaviruses (including SARS-CoV-2 & MERS-CoV):** Developing broad-spectrum protease inhibitors (e.g., CDI-988) for therapeutic use
- **Norovirus:** Creating inhibitors targeting RNA-dependent RNA polymerase and protease; currently in Phase 1 clinical trials
- **HCV (Hepatitis C Virus):** Developing ultra-short, pan-genotypic, oral antiviral regimens; targeting viral NS5B polymerase with non-nucleoside inhibitors

## Employees & Operations:
- As of December 31, 2024, the company employs **11 full-time employees**; 8 are engaged in clinical advancement, research, and development activities
- Also relies on contracts with clinical research organizations (CROs), CMOs, and consultants

## Financials (2024):
- **Revenue:** None (no products commercialized yet)
- **Net Loss:** approximately **$17.5 million**
- **Total Assets (as of Dec 31, 2024):** approx. **$13.5 million**
- **Cash & Restricted Cash:** approx. **$9.9 million**
- **No revenue from product sales**; expenses mainly from R&D and general administrative costs
- **R&D Expenses (2024):** ~$12.5 million
- **Admin Expenses (2024):** ~$5.3 million
- **Overall net loss:** Slightly decreased from ~$18 million in 2023

## Business Status:
- In early clinical or preclinical stages for all product candidates
- Has historically funded operations through equity offerings, including a private placement and an At-The-Market equity offering agreement
- Actively pursuing further funding to support ongoing and future research and development programs

## Key Collaborations:
- Terminated collaboration with Merck (effected in March 2024)
- Terminated licensing agreements with Kansas State University Research Foundation (effective March 2024)

## Market & Competition:
- Competing with large biotech and pharma companies like Roche, Gilead, Merck, Pfizer, Moderna, and others
- Focused on broad-spectrum antivirals to stay ahead of viral mutations and resistance issues
- No current regulatory approvals or commercial products

## Summary:
Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral drugs for viruses such as influenza, coronaviruses, norovirus, and hepatitis C. It employs cutting-edge, structure-based drug design techniques, with a small dedicated team of employees, and is in the preclinical/early clinical development stage with no revenue from sales yet. The company primarily funds its research through private equity, partnerships, and collaborations.

Cocrystal Pharma, Inc. is a biotechnology company focused on developing innovative antiviral therapeutics targeting significant viruses affecting human health.

# Cocrystal Pharma, Inc. Overview

## Company Description
Cocrystal Pharma, Inc. is a biotechnology company focused on the development of innovative antiviral therapeutics. The company leverages its proprietary technology platforms to design and develop novel drug candidates targeting viruses that significantly impact human health, such as influenza, hepatitis, and coronaviruses.

## Technology and Research Focus
- **Platform Technologies**: Cocrystal utilizes multiple proprietary technologies, including its RNA replication technology and molecular modeling platform to identify potential drug candidates.
- **Research Pipeline**: The company is involved in the research and development of new therapeutics aimed at addressing viral infections. This includes preclinical and clinical trials for its lead candidates.

## Key Highlights
- **Employees**: Cocrystal employs a skilled team of talent in drug discovery, clinical development, regulatory, and commercialization. The exact number of employees was not specified in the report.
- **Customers**: The nature of Cocrystal's business does not lend itself to a traditional customer base like retail companies; instead, they collaborate with research institutions, pharmaceutical companies, and partners within the biotech sector for the development and commercialization of their therapies.
  
## Financial Overview
- **Revenue**: The report does not provide specific revenue figures for the fiscal year ended December 31, 2023, but the company has historically received revenue through partnerships, grants, and research collaborations.
- **Income**: There are no exact details on net income provided in the report, as biotechnology companies often operate at a loss during the R&D phase due to high costs associated with drug development and clinical trials.

## Strategic Alliances
Cocrystal Pharma enters into collaborative agreements with other organizations and research institutions to enhance its research capabilities and market reach. The company aims to bring its novel antiviral solutions to market through these partnerships.

## Conclusion
Cocrystal Pharma, Inc. operates in the biotech field with a clear focus on antiviral therapeutics, utilizing advanced research technologies to innovate drug development. The specifics about customer base, employee count, and overall financial performance underscore the company's commitment and strategic approach to combating viral infections through scientific advancement.

Cocrystal Pharma, Inc.

10-K / March 31, 2025

10-K / April 17, 2024

10-K / March 31, 2025

Company Overview Summary

Company Name:

Industry:

Core Focus:

Technology and Approach:

Target Viruses and Medical Needs:

Employees & Operations:

Financials (2024):

Business Status:

Key Collaborations:

Market & Competition:

Summary: